mp.weixin.qq.com·· 6 hours agoScore81
NMPA Approves Enhertu for Pan-Tumor HER2 IHC 3+ Solid Tumor Indication
In brief
Daiichi Sankyo announced that trastuzumab deruxtecan (Enhertu) was approved by the NMPA on October 22, 2026 for HER2 IHC 3+ unresectable or metastatic solid tumors after prior treatment failure, making it the first pan-tumor HER2 ADC indication in China.
Source: mp.weixin.qq.com · mp.weixin.qq.com